Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus concurrent chemoradiotherapy for locally advanced esophageal squamous cell carcinoma
CTR20201135Phase 3Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of anlotinib, paclitaxel, cisplatin in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Jun 2020; status: active.
02
Drugs
anlotinibpaclitaxelcisplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20201135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201135.